Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Jetrea ocriplasmin regulatory update

The Alcon Inc. ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) said Health Canada approved Jetrea ocriplasmin to

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE